CD158b2 (KIR2DL3) Antibody, anti-human, REAlease®
Synonyms: KIR2DL3, Killer cell immunoglobulin-like receptor 2DL3
RECOMBINANT
Clone:
REAL145
Type of antibody:
Releasable antibodies, Primary antibodies, Recombinant antibodies
Applications:
FC Glossary
External link icon
Quality Assurance Certified ProductSatisfaction
guaranteed
more »
Select a conjugate:
Select a size:
Other sizes

Related products for CD158b2 (KIR2DL3) Antibody, anti-human, REAlease®

Flow cytometry applications
APC
FITC
Recommended dilution:
1:50
Data source:
Miltenyi Biotec
Conjugate:
APC
Used products:
130-115-189, 130-122-640, 130-115-291
Description:
Human peripheral blood mononuclear cells (PBMCs) were stained with REAlease CD158b2 (KIR2DL3)-APC (B) or with the corresponding REAL Control (A). REAlease CD158b2 (KIR2DL3)-APC was released using the REAlease Release Reagent (C). To show epitope accessibility after REAlease Complex release, the cells were washed with the REAlease Stop Reagent and restained with REAlease CD158b2 (KIR2DL3)-APC (D). Cells were labeled with CD56 antibodies in addition and analyzed by flow cytometry using the MACSQuant® Analyzer. Cell debris and dead cells were excluded from the analysis based on scatter signals and propidium iodide (PI) fluorescence.

Application imageView details view details

Application imageView details view details

Application imageView details view details

Application imageView details view details
Specifications for CD158b2 (KIR2DL3) Antibody, anti-human, REAlease®
Overview

Clone REAL145 is an antibody fragment derived from the full CD158b2 (KIR2DL3) antibody molecule. It displays no binding to Fc receptors. The recombinantly engineered antibody fragments are multimerized to form the REAlease Complex to bind markers with high avidity.

Clone REAL145 recognizes CD158b2 (KIR2DL3), a killer-cell immunoglobulin-like inhibitory receptor (KIR). Expressed by natural killer and a subset of T cells, KIR family of receptors are transmembrane glycoproteins and interact with MHC class I molecules. This interaction allows the KIR receptors to modulate the killing function of cells bearing them. The KIR proteins are categorized by the number of extracellular immunoglobulin domains (2D or 3D) and by the length (long (L) or short (S)) of the cytoplasmic domain. KIR proteins with the long cytoplasmic domain, such as CD158b2, transduce inhibitory signals via an immune tyrosine-based inhibitory motif (ITIM).

The REAlease Kits consist of the respective fluorochrome-conjugated REAlease Complexes and the REAlease Support Kit for removal of the REAlease Complexes and optional relabeling with different fluorochrome-conjugated REAlease Complexes.

Alternative names

KIR2DL3, Killer cell immunoglobulin-like receptor 2DL3

Detailed product information

Technical specifications

Clone
REAL145
Clonality
monoclonal
Isotype control
Control Antibody
Host
cell line
Type of antibody
Releasable antibodies, Primary antibodies, Recombinant antibodies
Species reactivity
human
Antigen
CD158b2 (KIR2DL3)
Distribution of antigen
T cells
RRID
AB_2751255, AB_2783966, AB_2751257, AB_2751251, AB_2751249, AB_2783967
Resources for CD158b2 (KIR2DL3) Antibody, anti-human, REAlease®
Certificates

To access a Certificate of Analysis (CoA) follow the link below and enter the specific lot of your product.

Get certificate

Should you wish to request additional documentation, such as a Safety Data Sheet (SDS) in other languages than English or Swedish, an SDS-replacement document, or a Certificate of Origin (CoO), please direct your inquiry to your local technical support team.

Contact technical support

Citations for CD158b2 (KIR2DL3) Antibody, anti-human, REAlease®
Publications
  1. Keaney, L. et al. (2004) Investigation of killer cell immunoglobulin-like receptor gene diversity III. KIR2DL3. Tissue Antigens 64 (2): 188-194
  2. Gendzekhadze, K. et al. (2009) Co-evolution of KIR2DL3 with HLA-C in a human population retaining minimal essential diversity of KIR and HLA class I ligands. Proc. Natl. Acad. Sci. U.S.A. 106: 18692-18697